12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

Bayer said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Xarelto rivaroxaban to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Xarelto is approved in Europe to prevent stroke...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >